Current Report Filing (8-k)
09 March 2022 - 11:48PM
Edgar (US Regulatory)
0001359931
false
0001359931
2022-03-09
2022-03-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 9, 2022
Protara Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-36694 |
|
20-4580525 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.) |
|
(IRS Employer
Identification No.) |
345 Park Avenue South
Third Floor
New York, NY |
|
10010 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (646) 844-0337
N/A
(Former name or former address, if changed since
last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
|
Trading Symbol(s) |
|
Name of each
exchange on which registered |
Common Stock, par value $0.001 per share |
|
TARA |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
| Item 2.02. | Results of Operations and Financial Condition. |
On March 9, 2022, Protara Therapeutics, Inc.
(the “Company”) announced its financial results for the quarter and year ended December 31, 2021 in the press release attached
hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this Item
2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing regardless of any general incorporation
language.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROTARA THERAPEUTICS, INC. |
|
|
|
|
Date: March 9, 2022 |
|
|
|
By: |
|
/s/ Blaine Davis |
|
|
|
|
|
|
Blaine Davis |
|
|
|
|
|
|
Chief Financial Officer |
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Protara Therapeutics (NASDAQ:TARA)
Historical Stock Chart
From Oct 2023 to Oct 2024